Sagittarius Life Science（3205）株式概要射手座生命科学股份有限公司は、台湾およびアジアにおいて、漢方薬、西洋薬、健康食品の研究、開発、販売を行っている。 詳細3205 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬過去5年間の収益は年間18.4%増加しました。 リスク分析キャッシュランウェイが1年未満である すべてのリスクチェックを見る3205 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW461,592 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA461,592 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$48.551.8k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-115m2b2016201920222025202620282031Revenue NT$308.0mEarnings NT$32.1mAdvancedSet Fair ValueView all narrativesSagittarius Life Science Corp 競合他社Dr. Wu SkincareSymbol: TPEX:6523Market cap: NT$4.0bMaywufaSymbol: TWSE:1731Market cap: NT$2.8bShiny Brands GroupSymbol: TPEX:6703Market cap: NT$3.7bLuo Lih-Fen HoldingSymbol: TWSE:6666Market cap: NT$2.0b価格と性能株価の高値、安値、推移の概要Sagittarius Life Science過去の株価現在の株価NT$48.5552週高値NT$67.0052週安値NT$43.95ベータ0.311ヶ月の変化-2.61%3ヶ月変化-10.92%1年変化-6.63%3年間の変化7.89%5年間の変化80.48%IPOからの変化-59.49%最新ニュースNew Risk • 2hNew major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.Reported Earnings • 2hSecond quarter 2026 earnings released: NT$0.02 loss per share (vs NT$0.33 loss in 2Q 2025)Second quarter 2026 results: NT$0.02 loss per share (improved from NT$0.33 loss in 2Q 2025). Revenue: NT$188.1m (up 67% from 2Q 2025). Net loss: NT$1.65m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.New Risk • Jul 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.21b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.21b market cap, or US$99.0m).Board Change • Jul 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jul 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Shun-xiong Xu was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 17Full year 2025 earnings released: NT$0.92 loss per share (vs NT$1.49 loss in FY 2024)Full year 2025 results: NT$0.92 loss per share. Revenue: NT$346.1m (down 26% from FY 2024). Net loss: NT$49.6m (loss widened 2.1% from FY 2024).最新情報をもっと見るRecent updatesNew Risk • 2hNew major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.Reported Earnings • 2hSecond quarter 2026 earnings released: NT$0.02 loss per share (vs NT$0.33 loss in 2Q 2025)Second quarter 2026 results: NT$0.02 loss per share (improved from NT$0.33 loss in 2Q 2025). Revenue: NT$188.1m (up 67% from 2Q 2025). Net loss: NT$1.65m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.New Risk • Jul 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.21b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.21b market cap, or US$99.0m).Board Change • Jul 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jul 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Shun-xiong Xu was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 17Full year 2025 earnings released: NT$0.92 loss per share (vs NT$1.49 loss in FY 2024)Full year 2025 results: NT$0.92 loss per share. Revenue: NT$346.1m (down 26% from FY 2024). Net loss: NT$49.6m (loss widened 2.1% from FY 2024).お知らせ • Feb 09Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026, at 09:30 Taipei Standard Time. Location: no,2, kung yeh rd., guantian district, tainan city TaiwanReported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.10 loss per share (vs NT$0.45 loss in 3Q 2024)Third quarter 2025 results: NT$0.10 loss per share (improved from NT$0.45 loss in 3Q 2024). Revenue: NT$92.9m (down 19% from 3Q 2024). Net loss: NT$6.77m (loss narrowed 54% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.09b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.09b market cap, or US$99.2m).New Risk • Sep 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Shareholders have been substantially diluted in the past year (108% increase in shares outstanding).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.50 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.50 loss in 2Q 2024). Revenue: NT$112.7m (down 4.8% from 2Q 2024). Net loss: NT$15.7m (loss narrowed 3.9% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (NT$1.07b market cap, or US$35.5m).Reported Earnings • May 18First quarter 2025 earnings released: NT$0.48 loss per share (vs NT$0.29 loss in 1Q 2024)First quarter 2025 results: NT$0.48 loss per share (further deteriorated from NT$0.29 loss in 1Q 2024). Revenue: NT$100.9m (down 14% from 1Q 2024). Net loss: NT$15.7m (loss widened 68% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 06Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025. Location: 3 floor building. f no,3, yuan ou st., nangang district, taipei city TaiwanReported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.45 loss per share (vs NT$0.34 loss in 3Q 2023)Third quarter 2024 results: NT$0.45 loss per share (further deteriorated from NT$0.34 loss in 3Q 2023). Revenue: NT$114.5m (up 8.2% from 3Q 2023). Net loss: NT$14.7m (loss widened 34% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$0.50 loss per share (vs NT$0.35 loss in 2Q 2023)Second quarter 2024 results: NT$0.50 loss per share (further deteriorated from NT$0.35 loss in 2Q 2023). Revenue: NT$118.3m (up 3.3% from 2Q 2023). Net loss: NT$16.4m (loss widened 43% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 19First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.43 loss in 1Q 2023)First quarter 2024 results: NT$0.29 loss per share (improved from NT$0.43 loss in 1Q 2023). Revenue: NT$117.0m (up 2.2% from 1Q 2023). Net loss: NT$9.35m (loss narrowed 33% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year.お知らせ • Mar 30Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024.Reported Earnings • Mar 25Full year 2023 earnings released: NT$1.69 loss per share (vs NT$2.28 loss in FY 2022)Full year 2023 results: NT$1.69 loss per share (improved from NT$2.28 loss in FY 2022). Revenue: NT$440.5m (down 17% from FY 2022). Net loss: NT$55.0m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • Aug 15Second quarter 2023 earnings released: NT$0.35 loss per share (vs NT$0.73 loss in 2Q 2022)Second quarter 2023 results: NT$0.35 loss per share (improved from NT$0.73 loss in 2Q 2022). Revenue: NT$114.6m (down 15% from 2Q 2022). Net loss: NT$11.5m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.80b market cap, or US$58.1m).Reported Earnings • Nov 16Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021)Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 13Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021)Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 19Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.56 loss in 2Q 2021)Second quarter 2022 results: NT$0.73 loss per share (down from NT$0.56 loss in 2Q 2021). Revenue: NT$134.5m (down 13% from 2Q 2021). Net loss: NT$23.8m (loss widened 30% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • May 19First quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.68 loss in 1Q 2021)First quarter 2022 results: NT$0.65 loss per share (up from NT$0.68 loss in 1Q 2021). Revenue: NT$134.3m (down 8.9% from 1Q 2021). Net loss: NT$21.3m (loss narrowed 3.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 03Full year 2021 earnings released: NT$2.66 loss per share (vs NT$2.27 loss in FY 2020)Full year 2021 results: NT$2.66 loss per share (down from NT$2.27 loss in FY 2020). Revenue: NT$587.6m (up 5.3% from FY 2020). Net loss: NT$86.4m (loss widened 17% from FY 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Apr 02Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022.Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$0.72 loss per share (vs NT$0.64 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: NT$145.9m (up 13% from 3Q 2020). Net loss: NT$23.6m (loss widened 13% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.56 loss per share (vs NT$0.72 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$153.7m (up 14% from 2Q 2020). Net loss: NT$18.3m (loss narrowed 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.31 loss in 1Q 2020)The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: NT$147.5m (flat on 1Q 2020). Net loss: NT$22.1m (loss widened 115% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.分析記事 • Apr 11We Think Sagittarius Life Science (GTSM:3205) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Apr 01Full year 2020 earnings released: NT$2.27 loss per share (vs NT$3.65 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$558.2m (up 27% from FY 2019). Net loss: NT$74.1m (loss narrowed 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 21New 90-day low: NT$31.50The company is down 5.0% from its price of NT$33.25 on 23 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 10.0% over the same period.Is New 90 Day High Low • Jan 06New 90-day low: NT$32.50The company is down 7.0% from its price of NT$35.05 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 5.0% over the same period.分析記事 • Dec 27Here's Why We're Not Too Worried About Sagittarius Life Science's (GTSM:3205) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Nov 15Third quarter 2020 earnings released: NT$0.64 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$128.9m (up 13% from 3Q 2019). Net loss: NT$20.9m (loss narrowed 25% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Oct 16New 90-day low: NT$33.95The company is down 17% from its price of NT$41.15 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: NT$36.50The company is down 14% from its price of NT$42.35 on 24 June 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.株主還元3205TW Personal ProductsTW 市場7D-0.1%-0.6%-1.9%1Y-6.6%-27.4%86.7%株主還元を見る業界別リターン: 3205過去 1 年間で-27.4 % の収益を上げたTW Personal Products業界を上回りました。リターン対市場: 3205は、過去 1 年間で86.7 % のリターンを上げたTW市場を下回りました。価格変動Is 3205's price volatile compared to industry and market?3205 volatility3205 Average Weekly Movement4.2%Personal Products Industry Average Movement4.2%Market Average Movement6.4%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.7%安定した株価: 3205 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 3205の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998n/an/awww.naturalbiokey.com射手座生命科学股份有限公司は、台湾とアジアにおいて、漢方薬、西洋薬、健康食品の研究、開発、販売を行っている。また、オーガニック食品、日用品、ペットフードの販売、バイオテクノロジーの研究開発も行っている。射手座ライフサイエンス社は1998年に設立され、台湾の台北を拠点としている。もっと見るSagittarius Life Science Corp 基礎のまとめSagittarius Life Science の収益と売上を時価総額と比較するとどうか。3205 基礎統計学時価総額NT$3.28b収益（TTM）-NT$16.46m売上高(TTM)NT$467.69m7.0xP/Sレシオ-199.2xPER（株価収益率3205 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計3205 損益計算書（TTM）収益NT$467.69m売上原価NT$425.56m売上総利益NT$42.12mその他の費用NT$58.59m収益-NT$16.46m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.24グロス・マージン9.01%純利益率-3.52%有利子負債／自己資本比率7.2%3205 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 20:00終値2026/08/20 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sagittarius Life Science Corp 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • 2hNew major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.
Reported Earnings • 2hSecond quarter 2026 earnings released: NT$0.02 loss per share (vs NT$0.33 loss in 2Q 2025)Second quarter 2026 results: NT$0.02 loss per share (improved from NT$0.33 loss in 2Q 2025). Revenue: NT$188.1m (up 67% from 2Q 2025). Net loss: NT$1.65m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.21b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.21b market cap, or US$99.0m).
Board Change • Jul 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Shun-xiong Xu was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 17Full year 2025 earnings released: NT$0.92 loss per share (vs NT$1.49 loss in FY 2024)Full year 2025 results: NT$0.92 loss per share. Revenue: NT$346.1m (down 26% from FY 2024). Net loss: NT$49.6m (loss widened 2.1% from FY 2024).
New Risk • 2hNew major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.
Reported Earnings • 2hSecond quarter 2026 earnings released: NT$0.02 loss per share (vs NT$0.33 loss in 2Q 2025)Second quarter 2026 results: NT$0.02 loss per share (improved from NT$0.33 loss in 2Q 2025). Revenue: NT$188.1m (up 67% from 2Q 2025). Net loss: NT$1.65m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.21b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.21b market cap, or US$99.0m).
Board Change • Jul 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Shun-xiong Xu was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 17Full year 2025 earnings released: NT$0.92 loss per share (vs NT$1.49 loss in FY 2024)Full year 2025 results: NT$0.92 loss per share. Revenue: NT$346.1m (down 26% from FY 2024). Net loss: NT$49.6m (loss widened 2.1% from FY 2024).
お知らせ • Feb 09Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026, at 09:30 Taipei Standard Time. Location: no,2, kung yeh rd., guantian district, tainan city Taiwan
Reported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.10 loss per share (vs NT$0.45 loss in 3Q 2024)Third quarter 2025 results: NT$0.10 loss per share (improved from NT$0.45 loss in 3Q 2024). Revenue: NT$92.9m (down 19% from 3Q 2024). Net loss: NT$6.77m (loss narrowed 54% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.09b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.09b market cap, or US$99.2m).
New Risk • Sep 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Shareholders have been substantially diluted in the past year (108% increase in shares outstanding).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.50 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.50 loss in 2Q 2024). Revenue: NT$112.7m (down 4.8% from 2Q 2024). Net loss: NT$15.7m (loss narrowed 3.9% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (NT$1.07b market cap, or US$35.5m).
Reported Earnings • May 18First quarter 2025 earnings released: NT$0.48 loss per share (vs NT$0.29 loss in 1Q 2024)First quarter 2025 results: NT$0.48 loss per share (further deteriorated from NT$0.29 loss in 1Q 2024). Revenue: NT$100.9m (down 14% from 1Q 2024). Net loss: NT$15.7m (loss widened 68% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 06Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025. Location: 3 floor building. f no,3, yuan ou st., nangang district, taipei city Taiwan
Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.45 loss per share (vs NT$0.34 loss in 3Q 2023)Third quarter 2024 results: NT$0.45 loss per share (further deteriorated from NT$0.34 loss in 3Q 2023). Revenue: NT$114.5m (up 8.2% from 3Q 2023). Net loss: NT$14.7m (loss widened 34% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$0.50 loss per share (vs NT$0.35 loss in 2Q 2023)Second quarter 2024 results: NT$0.50 loss per share (further deteriorated from NT$0.35 loss in 2Q 2023). Revenue: NT$118.3m (up 3.3% from 2Q 2023). Net loss: NT$16.4m (loss widened 43% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 19First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.43 loss in 1Q 2023)First quarter 2024 results: NT$0.29 loss per share (improved from NT$0.43 loss in 1Q 2023). Revenue: NT$117.0m (up 2.2% from 1Q 2023). Net loss: NT$9.35m (loss narrowed 33% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year.
お知らせ • Mar 30Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024.
Reported Earnings • Mar 25Full year 2023 earnings released: NT$1.69 loss per share (vs NT$2.28 loss in FY 2022)Full year 2023 results: NT$1.69 loss per share (improved from NT$2.28 loss in FY 2022). Revenue: NT$440.5m (down 17% from FY 2022). Net loss: NT$55.0m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • Aug 15Second quarter 2023 earnings released: NT$0.35 loss per share (vs NT$0.73 loss in 2Q 2022)Second quarter 2023 results: NT$0.35 loss per share (improved from NT$0.73 loss in 2Q 2022). Revenue: NT$114.6m (down 15% from 2Q 2022). Net loss: NT$11.5m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.80b market cap, or US$58.1m).
Reported Earnings • Nov 16Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021)Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 13Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021)Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 19Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.56 loss in 2Q 2021)Second quarter 2022 results: NT$0.73 loss per share (down from NT$0.56 loss in 2Q 2021). Revenue: NT$134.5m (down 13% from 2Q 2021). Net loss: NT$23.8m (loss widened 30% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • May 19First quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.68 loss in 1Q 2021)First quarter 2022 results: NT$0.65 loss per share (up from NT$0.68 loss in 1Q 2021). Revenue: NT$134.3m (down 8.9% from 1Q 2021). Net loss: NT$21.3m (loss narrowed 3.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 03Full year 2021 earnings released: NT$2.66 loss per share (vs NT$2.27 loss in FY 2020)Full year 2021 results: NT$2.66 loss per share (down from NT$2.27 loss in FY 2020). Revenue: NT$587.6m (up 5.3% from FY 2020). Net loss: NT$86.4m (loss widened 17% from FY 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Apr 02Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022.
Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$0.72 loss per share (vs NT$0.64 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: NT$145.9m (up 13% from 3Q 2020). Net loss: NT$23.6m (loss widened 13% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.56 loss per share (vs NT$0.72 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$153.7m (up 14% from 2Q 2020). Net loss: NT$18.3m (loss narrowed 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.31 loss in 1Q 2020)The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: NT$147.5m (flat on 1Q 2020). Net loss: NT$22.1m (loss widened 115% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
分析記事 • Apr 11We Think Sagittarius Life Science (GTSM:3205) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Apr 01Full year 2020 earnings released: NT$2.27 loss per share (vs NT$3.65 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$558.2m (up 27% from FY 2019). Net loss: NT$74.1m (loss narrowed 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 21New 90-day low: NT$31.50The company is down 5.0% from its price of NT$33.25 on 23 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Jan 06New 90-day low: NT$32.50The company is down 7.0% from its price of NT$35.05 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 5.0% over the same period.
分析記事 • Dec 27Here's Why We're Not Too Worried About Sagittarius Life Science's (GTSM:3205) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Nov 15Third quarter 2020 earnings released: NT$0.64 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$128.9m (up 13% from 3Q 2019). Net loss: NT$20.9m (loss narrowed 25% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Oct 16New 90-day low: NT$33.95The company is down 17% from its price of NT$41.15 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: NT$36.50The company is down 14% from its price of NT$42.35 on 24 June 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.
